跳至主要内容
临床试验/2024-516141-39-00
2024-516141-39-00招募中4 期

EFFECT OF ONCE VS TWICE DAILY ADMINISTRATION OF CORTICOSTEROIDS ON BLOOD GLUCOSE IN PATIENTS WITH ANCA-VASCULITIS MEASURED BY CONTINUOUS BLOOD GLUCOSE MONITORING - A PILOT STUDY

Medical University Of Graz1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2024年11月18日最近更新:
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
10
试验地点
1
主要终点
Mean time in target range (70-180mg/dl) measured by blinded continuous glucose measurement (CGM).

研究概览

简要总结

Evaluation of whether splitting the cortisone dose to a twice daily dose leads to increased time in the glucose target range.

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Written agreement to participate in the study after detailed explanation of the study
  • Male or female patients
  • New diagnosis of ANCA-associated vasculitis or a relapse of a known ANCA vasculitis
  • Age: ≥18-80 years at the time of biopsy
  • Aprednislon dose of 1mg/kg body weight at the time of inclusion
  • Wants to wear a CGM system for the duration of the study and to receive insulin therapy as needed

排除标准

  • Known diabetes mellitus
  • Women capable of giving birth who are pregnant, breastfeeding, wish to become pregnant or do not use adequate contraception.
  • Skin changes or concomitant circumstances that prevent the placement of a glucose sensor in the examiner's assessment (e.g. scar tissue)
  • Current participation in another clinical trial that would affect study results
  • Relevant acute or chronic disease that, in the investigator's estimation, could affect the patient's safety or affect the study results.
  • Patient's inability to follow study procedures as required
  • Inability of the patient to understand the consent form

结局指标

主要结局

Mean time in target range (70-180mg/dl) measured by blinded continuous glucose measurement (CGM).

Mean time in target range (70-180mg/dl) measured by blinded continuous glucose measurement (CGM).

次要结局

  • CRP at initial diagnosis and during course of treatment
  • Leukocytes at initial diagnosis and during course of disease
  • Number and percent of glucose values (CGM, BG) in the following ranges: 0-<40mg/dl (blood glucose only), 40-<70mg/dl, 70-<100mg/dl, 100-<140mg/dl, 140-<180mg/dl, 180-<300mg/dl, ≥300mg/dl
  • Time of glucose values (CGM, BG) in the following ranges: 0-<40mg/dl (blood glucose only), 40-<70mg/dl, 70-<100mg/dl, 100-<140mg/dl, 140-<180mg/dl, 180-<300mg/dl, ≥300mg/dl
  • Average daily blood glucose based on preprandial and bedtime glucose values: total and per treatment day
  • Mean blood glucose before the respective times: before breakfast, before lunch, before dinner, at bedtime
  • Mean blood glucose before start of study during in-patient stay
  • Number of insulin injections per day
  • Relevant concomitant medication during inpatient stay (corticosteroids, parenteral nutrition, oral antidiabetics)
  • Relevant diabetes medication for discharge from inpatient care (insulin therapy - type and dose, oral antidiabetics)
  • HbA1c
  • Sex
  • Age
  • Additionally affected organs
  • Antibody titer (ANCA, anti-GBM, anti-ds-DNS,..) at initial diagnosis and during course of disease
  • Thrombocytes at initial diagnosis and during course of disease
  • GFR at initial diagnosis and during course of disease
  • Creatinine at initial diagnosis and during course of disease
  • Protein and albuminuria at initial diagnosis and during course of disease
  • Urinary sediment at initial diagnosis and in the course of the disease
  • Therapy after initial diagnosis and during course (e.g. switch to rituximab)
  • Birmingham Vasculitis Score (BVAS) on discharge
  • Quality of life measured by the SF-36 and KDQOL questionnaire

研究者

发起方
Medical University Of Graz
申办方类型
Educational Institution
责任方
Principal Investigator
主要研究者

Coordination center for Clinical Trials

Scientific

Medical University Of Graz

研究点 (1)

Loading locations...

相似试验